Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 April 2021 | Story Financial Aid

Dear Student

Please take note that the NSFAS appeals process is now open.

FIRST TIME AND NEW APPLICANTS

First time1 and new applicants2 for NSFAS funding for 2021 whose applications were rejected by NSFAS must submit their appeal electronically on the MyNSFAS portal. Financial Aid offices may not accept manual forms for this group of students and may not submit manual appeals for this group to NSFAS. You will be able to track your status on the MyNSFAS portal.

SENIOR RETURNING/CONTINUING STUDENTS

Please see appeal form attached.

The following process is ONLY applicable to NSFAS returning/continuing students and exclude first time
and new applicants for NSFAS funding in 2021.

The following documents must be submitted from your “ufs4life” email address for your appeal to be
considered:
  • 1. Completed and signed appeal form attached herewith.
  • 2. Ensure that the relevant box indicating the reason for your appeal is checked.
  • 3. Signed motivation
  • 4. Supporting documents (e.g. Medical certificates, death certificate etc.) Your appeal can
  • unfortunately not be considered in the absence of documentation in support of your reason and
  • motivation for the appeal.
Please note that NSFAS confirmed that you cannot appeal if you exceeded the N+ period. You can only
submit an appeal for one of the reasons provided on the appeal form.

Please submit the abovementioned required documents as one single combined attachment in legible 
PDF format to your campus specific e-mail address below:
Bloemfontein Campus – NSFASAppealsBfn@ufs.ac.za
Qwaqwa Campus – NSFASAppealsQQ@ufs.ac.za
The closing date for submission of appeals is 30 April 2021 at 16:00 and no appeals will be accepted after
this date.

Issued by

Financial Aid

 

News Archive

Otorhinolaryngology research hopes to decrease morbidity
2016-10-04

Description: Prof Riaz Seedat Tags: Prof Riaz Seedat

Prof Riaz Seedat, Head of the
Department of
Otorhinolaryngology at the UFS

Prof Riaz Seedat, Head of the Department of Otorhinolaryngology at the UFS is a world-renowned ear, nose and throat specialist and researcher. He is also a National Research Foundation C3 rated scientist.

He is conducting his research in ear, nose and throat (ENT) pathology in a developing world setting, particularly focusing on recurrent respiratory papillomatosis and other ENT conditions. “This condition is caused by human papillomavirus (HPV), infective conditions as well as allergic rhinitis,” said Prof Seedat.

Current research is aimed at further describing the epidemiology of recurrent respiratory papillomatosis, identification of the HPV variants responsible for causing the condition and markers of disease aggressiveness.

The research has led to various international partnerships such as the multicentre collaborative studies, “Genetic Susceptibility to Papilloma-induced Voice Disturbance” at the Centre for Genomic Sciences at the Allegheny-Singer Research Institute in Pittsburgh, United States, and the HPV6/11 Global Diversity Consortium at the University of Ljubljana in Slovenia.

Although most head and neck squamous cell carcinomas are caused by excessive tobacco and alcohol use, there is an increasing body of evidence to show that HPV causes a subset of head and neck squamous cell carcinomas. However, there are few studies on the role of HPV in head and neck neoplasms in developing countries.

“Through the research we have shown that recurrent respiratory papillomatosis, caused by HPV, is not as rare in South Africa as it is in developed countries and that patients usually present respiratory papillomatosis at an advanced stage when the condition is life-threatening,” said Prof Seedat.

“It is hoped that this research will help us to address the morbidity caused by ENT conditions common in developing countries,” said Prof Seedat.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept